

# Gaetano Zaccara

POSIZIONE PER LA QUALE SI  
CONCORRE  
POSIZIONE RICOPERTA  
OCCUPAZIONE DESIDERATA  
TITOLO DI STUDIO PER LA  
QUALE SI CONCORRE

## Esperto di Alta Qualificazione per l'anno accademico 2015-2016

ESPERIENZA  
PROFESSIONALE

Dal 2009 Direttore della U.O. di Neurologia della Azienda Sanitaria di Firenze, Presidio ospedaliero S Giovanni di Dio  
Dal 2006 Direttore della U.O. di Neurologia della Azienda Sanitaria di Firenze, Presidio ospedaliero Palagi  
Dal 1997 Direttore U.O. Neurologia Azienda Sanitaria di Firenze, presidio ospedaliero S M Nuova  
Dal 1992 Direttore della U.O. di Neurologia della USL 10 E di Firenze  
Dal 1980 assistente presso la Clinica Neurologica II, Università di Firenze

Sostituire con date (da - a)

Direttore U.O. Neurologia, USL Toscana Centro, Firenze

USL Toscana Centro, Piazza S.M. Nuova, Firenze,

- Responsabile Commissione Farmaco, Lega Italiana Contro l'epilessia
- Responsabile Commissione sulle malattie neurologiche croniche del Dipartimento Interaziendale della Toscana Centro

### ISTRUZIONE E FORMAZIONE

Sostituire con date (da - a)

Ha partecipato in qualità di docente a diversi corsi nazionali ed internazionali sulla terapia della epilessia

Lega Internazionale contro l'epilessia (EUREPA)

- Sostituire con un elenco delle principali materie trattate o abilità acquisite

### COMPETENZE PERSONALI

Lingua madre

Italiano

Altre lingue

Sostituire con la lingua

Sostituire con la lingua

	COMPRESIONE		PARLATO		PRODUZIONE SCRITTA
	Ascolto	Letture	Interazione	Produzione orale	
Inglese	Inserire il livello	Inserire il livello	Inserire il livello	Inserire il livello	Inserire il livello
Buona conoscenza della lingua					
	Inserire il livello	Inserire il livello	Inserire il livello	Inserire il livello	Inserire il livello
Sostituire con il nome del certificato di lingua acquisito. Inserire il livello, se conosciuto					

Livelli: A1/2 Livello base - B1/2 Livello intermedio - C1/2 Livello avanzato  
Quadro Comune Europeo di Riferimento delle Lingue

Competenze comunicative	▪ possiedo buone competenze comunicative acquisite attraverso i corsi e le relazioni ai congressi
Competenze organizzative e gestionali	Direttore di Unità Operativa di Neurologia che opera in 4 diversi ospedali
Competenze professionali	▪ Neurologo clinico particolarmente specializzato nella terapia della epilessia
Competenze informatiche	▪ buona padronanza degli strumenti Microsoft Office
Altre competenze	▪ Ottimo sciatore
Patente di guida	Patente B

#### ULTERIORI INFORMAZIONI

---

Pubblicazioni	Si veda allegato 1
Presentazioni	
Progetti	
Conferenze	Ha tenuto numerose relazioni a congressi nazionali ed internazionali
Seminari	
Riconoscimenti e premi	
Appartenenza a gruppi / associazioni	
Referenze	
Dati personali	

#### ALLEGATI


---

- Allegato 1 Bibliografia

Allegato

*Il sottoscritto acconsente alla pubblicazione del presente curriculum vitae sul sito dell'Università di Ferrara.*

FIRMA



**Pubblicazioni su riviste internazionali censite da Pub Med del dr G Zaccara (dalla più recente alle meno recenti)**

- 1: Zaccara G, Schmidt D. Do traditional anti-seizure drugs have a future?: A review of potential anti-seizure drugs in clinical development. *Pharmacol Res.* 2015 Dec 12. pii: S1043-6618(15)00288-1.
- 2: Bandini A, Orlandi S, Giovannelli F, Felici A, Cincotta M, Clemente D, Vanni P, Zaccara G, Manfredi C. Markerless Analysis of Articulatory Movements in Patients With Parkinson's Disease. *J Voice.* 2015 Nov 24. pii: S0892-1997(15)00232-5
- 3: Verrotti A, Prezioso G, Di Sabatino F, Franco V, Chiarelli F, Zaccara G. The adverse event profile of levetiracetam: A meta-analysis on children and adults. *Seizure.* 2015 Sep;31:49-55.
- 4: Verrotti A, Mencaroni E, Castagnino M, Zaccara G. Foetal safety of old and new antiepileptic drugs. *Expert Opin Drug Saf.* 2015 Oct;14(10):1563-71.
- 5: Cincotta M, Giovannelli F, Chiaramonti R, Bianco G, Godone M, Battista D, Cardinali C, Borgheresi A, Sighinolfi A, D'Avanzo AM, Breschi M, Dine Y, Lino M, Zaccara G, Viggiano MP, Rossi S. No effects of 20 Hz-rTMS of the primary motor cortex in vegetative state: A randomised, sham-controlled study. *Cortex.* 2015 Oct;71:368-76. doi: 10.1016/j.cortex.2015.07.027.
- 6: Cincotta M, Giovannelli F, Borgheresi A, Tramacere L, Viggiano MP, Zaccara G. A Meta-analysis of the Cortical Silent Period in Epilepsies. *Brain Stimul.* 2015 Jul-Aug;8(4):693-701.
- 7: Zaccara G, Giovannelli F, Cincotta M, Carelli A, Verrotti A. Clinical utility of eslicarbazepine: current evidence. *Drug Des Devel Ther.* 2015 Feb 10;9:781-9.
- 8: Zaccara G, Giovannelli F, Schmidt D. Placebo and nocebo responses in drug trials of epilepsy. *Epilepsy Behav.* 2015 Feb;43:128-34.
- 9: Verrotti A, Milioni M, Zaccara G. Safety and efficacy of diazepam autoinjector for the management of epilepsy. *Expert Rev Neurother.* 2015 Feb;15(2):127-33
- 10: Zaccara G, Perucca E. Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs. *Epileptic Disord.* 2014 Dec;16(4):409-31.
- 11: Chisci E, Pigozzi C, Troisi N, Tramacere L, Zaccara G, Cincotta M, Ercolini L, Michelagnoli S. "Thirty-day neurologic improvement associated with early versus delayed carotid endarterectomy in symptomatic patients". *Ann Vasc Surg.* 2015 Apr;29(3):435-42.
- 12: Loiacono G, Masci M, Zaccara G, Verrotti A. The treatment of neonatal seizures: focus on Levetiracetam. *J Matern Fetal Neonatal Med.* 2016;29(1):69-74.
- 13: Giovannelli F, Zaccara G, Cincotta M, Loiacono G, Verrotti A. Characterization of the adverse events profile of placebo-treated patients in randomized controlled trials on drug-resistant focal epilepsies. *J Neurol.* 2015 Jun;262(6):1401-6.
- 14: Zaccara G, Giovannelli F, Franco V, Cincotta M, Tramacere L, Verrotti A. Adverse events, placebo and nocebo effects in placebo-treated paediatric patients with refractory focal epilepsies. Analysis of double-blind studies. *Epilepsy Res.* 2014 Dec;108(10):1685-93.
- 15: Giovannelli F, Ragazzoni A, Battista D, Tarantino V, Del Sordo E, Marzi T, Zaccara G, Avanzini G, Viggiano MP, Cincotta M. "...The times they aren't a-changin'..." rTMS does not affect basic mechanisms of temporal discrimination: a pilot study with ERPs. *Neuroscience.* 2014 Oct 10;278:302-12.
- 16: Salvadori E, Poggesi A, Pracucci G, Inzitari D, Pantoni L; VMCI-Tuscany Study Group. Development and psychometric properties of a neuropsychological battery for mild cognitive impairment with small vessel disease: the VMCI-Tuscany Study. *J Alzheimers Dis.* 2015;43(4):1313-23.
- 17: Zaccara G, Giovannelli F, Cincotta M, Loiacono G, Verrotti A. Adverse events of placebo-treated, drug-resistant, focal epileptic patients in randomized controlled trials: a systematic review. *J Neurol.* 2015 Mar;262(3):501-15.
- 18: Zaccara G, Almas M, Pitman V, Knapp L, Posner H. Efficacy and safety of pregabalin versus levetiracetam as adjunctive therapy in patients with partial seizures: a randomized, double-blind, noninferiority trial. *Epilepsia.* 2014 Jul;55(7):1048-57.
- 19: Zaccara G, Giovannelli F, Bell GS, Sander JW. Network meta-analyses of antiepileptic drug efficacy and tolerability in drug-resistant focal epilepsies: a clinical perspective. *Eur J Clin Pharmacol.* 2014 Jun;70(6):647-54.
- 20: Beretta S, Beghi E, Messina P, Gerardi F, Pescini F, La Licata A, Specchio L, Ferrara M, Canevini MP, Turner K, La Briola F, Franceschetti S, Binelli S, Giglioli I, Galimberti CA, Fattore C, Zaccara G, Tramacere L, Sasanelli F, Pirovano M, Ferrarese C. Comprehensive educational plan for patients with epilepsy and comorbidity (EDU-COM): a pragmatic randomised trial. *J Neurol Neurosurg Psychiatry.* 2014 Aug;85(8):889-94.
- 21: Verrotti A, Loiacono G, Rossi A, Zaccara G. Eslicarbazepine acetate: an update on efficacy and safety in epilepsy. *Epilepsy Res.* 2014 Jan;108(1):1-10. doi: 10.1016/j.eplepsyres.2013.10.005.

- 22: Beghi E, Giussani G, Grosso S, Iudice A, La Neve A, Pisani F, Specchio LM, Verrotti A, Capovilla G, Michelucci R, Zaccara G. Withdrawal of antiepileptic drugs: guidelines of the Italian League Against Epilepsy. *Epilepsia*. 2013 Oct;54 Suppl 7:2-12.
- 23: Verrotti A, Loiacono G, Di Sabatino F, Zaccara G. The adverse event profile of zonisamide: a meta-analysis. *Acta Neurol Scand*. 2013 nov;128(5):297-304. doi: 10.1111/ane.12147.
- 24: Zaccara G, Giovannelli F, Cincotta M, Iudice A. AMPA receptor inhibitors for the treatment of epilepsy: the role of perampanel. *Expert Rev Neurother*. 2013 Jun;13(6):647-55.
- 25: Zaccara G, Sisodiya SM, Giovannelli F, Walker MC, Heaney DC, Angus-Leppan H, Wehner T, Eriksson SH, Liu R, Rugg-Gunn F, Shorvon SD, Sander JW. Network meta-analysis and the comparison of efficacy and tolerability of anti-epileptic drugs for treatment of refractory focal epilepsy. *Br J Clin Pharmacol*. 2013 Nov;76(5):827-8.
- 26: Zaccara G, Giovannelli F, Maratea D, Fadda V, Verrotti A. Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine. *Seizure*. 2013 Sep;22(7):528-36.
- 27: Zaccara G, Giovannelli F, Cincotta M, Verrotti A, Grillo E. The adverse event profile of perampanel: meta-analysis of randomized controlled trials. *Eur J Neurol*. 2013 Aug;20(8):1204-11.
- 28: Franco V, Crema F, Iudice A, Zaccara G, Grillo E. Novel treatment options for epilepsy: focus on perampanel. *Pharmacol Res*. 2013 Apr;70(1):35-40.
- 29: Giovannelli F, Innocenti I, Rossi S, Borgheresi A, Ragazzoni A, Zaccara G, Viggiano MP, Cincotta M. Role of the dorsal premotor cortex in rhythmic auditory-motor entrainment: a perturbational approach by rTMS. *Cereb Cortex*. 2014 Apr;24(4):1009-16.
- 31: Verrotti A, Loiacono G, Olivieri C, Zulli E, Zaccara G. Lacosamide in patients with pharmacoresistant epilepsy. *Expert Opin Pharmacother*. 2012 Oct;13(14):2065-72.
- 32: Zaccara G, Perucca P, Loiacono G, Giovannelli F, Verrotti A. The adverse event profile of lacosamide: a systematic review and meta-analysis of randomized controlled trials. *Epilepsia*. 2013 Jan;54(1):66-74.
- 33: Guerrini R, Zaccara G, la Marca G, Rosati A. Safety and tolerability of antiepileptic drug treatment in children with epilepsy. *Drug Saf*. 2012 Jul 1;35(7):519-33.
- 34: Giovannelli F, Banfi C, Borgheresi A, Fiori E, Innocenti I, Rossi S, Zaccara G, Viggiano MP, Cincotta M. The effect of music on corticospinal excitability is related to the perceived emotion: a transcranial magnetic stimulation study. *Cortex*. 2013 Mar;49(3):702-10.
- 35: Zaccara G, Perucca P, Gangemi PF. The adverse event profile of pregabalin across different disorders: a meta-analysis. *Eur J Clin Pharmacol*. 2012 Jun;68(6):903-12.
- 36: Beghi E, D'Alessandro R, Beretta S, Consoli D, Crespi V, Delaj L, Gandolfo C, Greco G, La Neve A, Manfredi M, Mattana F, Musolino R, Provinciali L, Santangelo M, Specchio LM, Zaccara G; Epistroke Group. Incidence and predictors of acute symptomatic seizures after stroke. *Neurology*. 2011 Nov 15;77(20):1785-93.
- 37: Zaccara G, Tramacere L, Cincotta M. Drug safety evaluation of zonisamide for the treatment of epilepsy. *Expert Opin Drug Saf*. 2011 Jul;10(4):623-31.
- 38: Manna I, Gambardella A, Bianchi A, Striano P, Tozzi R, Aguglia U, Beccaria F, Benna P, Camprostrini R, Canevini MP, Condino F, Durisotti C, Elia M, Giallonardo AT, Iudice A, Labate A, La Neve A, Michelucci R, Muscas GC, Paravidino R, Zaccara G, Zucca C, Zara F, Perucca E. A functional polymorphism in the SCN1A gene does not influence antiepileptic drug responsiveness in Italian patients with focal epilepsy. *Epilepsia*. 2011 May;52(5):e40-4.
- 39: Zaccara G, Gangemi P, Perucca P, Specchio L. The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials. *Epilepsia*. 2011 Apr;52(4):826-36.
- 40: Francia A, Luzi G, Morreale M, Vanacore N; Italian Epilepsy and Immunity Relationship Study Group. Can immune disorders influence therapeutic approaches in treatment of epilepsy among neurologists? A first cooperative national recognition in Italy. *Int J Immunopathol Pharmacol*. 2010 Oct-Dec;23(4):1267-9.
- 41: Cincotta M, Giovannelli F, Borgheresi A, Balestrieri F, Toscani L, Zaccara G, Carducci F, Viggiano MP, Rossi S. Optically tracked neuronavigation increases the stability of hand-held focal coil positioning: evidence from "transcranial" magnetic stimulation-induced electrical field measurements. *Brain Stimul*. 2010 Apr;3(2):119-23.
- 42: Borgheresi A, Espay AJ, Giovannelli F, Vanni P, Zaccara G, Cincotta M. Congenital mirror movements in Parkinson's disease: clinical and neurophysiological observations. *Mov Disord*. 2010 Jul 30;25(10):1520-3.

- 43: Pallanti S, Borgheresi A, Pampaloni I, Giovannelli F, Bernardi S, Cantisani A, Zaccara G, Cincotta M. Motor cortex excitability correlates with novelty seeking in social anxiety: a transcranial magnetic stimulation investigation. *J Neurol*. 2010 Aug;257(8):1362-8.
- 44: Giovannelli F, Silingardi D, Borgheresi A, Feurra M, Amati G, Pizzorusso T, Viggiano MP, Zaccara G, Berardi N, Cincotta M. Involvement of the parietal cortex in perceptual learning (Eureka effect): an interference approach using rTMS. *Neuropsychologia*. 2010 May;48(6):1807-12.
- 45: Pallanti S, Castellini G, Chamberlain SR, Quercioli L, Zaccara G, Fineberg NA. Cognitive event-related potentials differentiate schizophrenia with obsessive-compulsive disorder (schizo-OCD) from OCD and schizophrenia without OC symptoms. *Psychiatry Res*. 2009 Nov 30;170(1):52-60.
- 46: Giovannelli F, Borgheresi A, Balestrieri F, Zaccara G, Viggiano MP, Cincotta M, Ziemann U. Modulation of interhemispheric inhibition by volitional motor activity: an ipsilateral silent period study. *J Physiol*. 2009 Nov 15;587(Pt 22):5393-410.
- 47: Zaccara G, Specchio LM. Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature. *europsychiatr Dis Treat*. 2009;5:249-59.
- 48: Zaccara G. Neurological comorbidity and epilepsy: implications for treatment. *Acta Neurol Scand*. 2009 Jul;120(1):1-15
- 49: Bracco L, Giovannelli F, Bessi V, Borgheresi A, Di Tullio A, Sorbi S, Zaccara G, Cincotta M. Mild cognitive impairment: loss of linguistic task-induced changes in motor cortex excitability. *Neurology*. 2009 Mar 10;72(10):928-34.
- 50: Gil-Nagel A, Zaccara G, Baldinetti F, Leon T. Add-on treatment with pregabalin for partial seizures with or without generalisation: pooled data analysis of four randomised placebo-controlled trials. *Seizure*. 2009 Apr;18(3):184-92. doi: 10.1016/j.seizure.2008.09.004. Epub 2008 Oct 31. Erratum in: *Seizure*. 2009 Dec;18(10):719.
- 51: Viggiano MP, Giovannelli F, Borgheresi A, Feurra M, Berardi N, Pizzorusso T, Zaccara G, Cincotta M. Disruption of the prefrontal cortex function by rTMS produces a category-specific enhancement of the reaction times during visual object identification. *Neuropsychologia*. 2008 Sep;46(11):2725-31.
- 52: Zaccara G, Gangemi PF, Cincotta M. Central nervous system adverse effects of new antiepileptic drugs. A meta-analysis of placebo-controlled studies. *Seizure*. 2008 Jul;17(5):405-21.
- 53: Krämer G, Biraben A, Carreno M, Guekht A, de Haan GJ, Jedrzejczak J, Josephs D, van Rijckevorsel K, Zaccara G. Current approaches to the use of generic antiepileptic drugs. *Epilepsy Behav*. 2007 Aug;11(1):46-52.
- 54: Zaccara G, Franciotta D, Perucca E. Idiosyncratic adverse reactions to antiepileptic drugs. *Epilepsia*. 2007 Jul;48(7):1223-44.
- 55: Cantello R, Rossi S, Varrasi C, Olivelli M, Civardi C, Bartalini S, Vatti G, Cincotta M, Borgheresi A, Zaccara G, Quartarone A, Crupi D, Laganà A, Inghilleri M, Giallonardo AT, Berardelli A, Pacifici L, Ferreri F, Tombini M, Gilio F, Quarato P, Conte A, Manganotti P, Bongiovanni LG, Monaco F, Ferrante D, Rossini PM. Slow repetitive TMS for drug-resistant epilepsy: clinical and EEG findings of a placebo-controlled trial. *Epilepsia*. 2007 Feb;48(2):366-74.
- 56: Perucca E, Albani F, Capovilla G, Bernardina BD, Michelucci R, Zaccara G. Recommendations of the Italian League against Epilepsy working group on generic products of antiepileptic drugs. *Epilepsia*. 2006;47 Suppl 5:16-20.
- 57: Zaccara G, Messori A, Cincotta M, Burchini G. Comparison of the efficacy and tolerability of new antiepileptic drugs: what can we learn from long-term studies? *Acta Neurol Scand*. 2006 Sep;114(3):157-68.
- 58: Giovannelli F, Borgheresi A, Balestrieri F, Ragazzoni A, Zaccara G, Cincotta M, Ziemann U. Role of the right dorsal premotor cortex in "physiological" mirror EMG activity. *Exp Brain Res*. 2006 Nov;175(4):633-40.
- 59: Viggiano MP, Gori G, Zaccara G, Righi S, Vannucci M, Giovannelli F. Category-specific visual identification of filtered objects in Alzheimer's disease. *Arch Gerontol Geriatr*. 2007 Mar-Apr;44(2):125-39.
- 60: Cincotta M, Giovannelli F, Borgheresi A, Balestrieri F, Vanni P, Ragazzoni A, Zaccara G, Ziemann U. Surface electromyography shows increased mirroring in Parkinson's disease patients without overt mirror movements. *Mov Disord*. 2006 Sep;21(9):1461-5.
- 61: Cincotta M, Borgheresi A, Balestrieri F, Giovannelli F, Ragazzoni A, Vanni P, Benvenuti F, Zaccara G, Ziemann U. Mechanisms underlying mirror movements in Parkinson's disease: a transcranial magnetic stimulation study. *Mov Disord*. 2006 Jul;21(7):1019-25.
- 62: Cincotta M, Giovannelli F, Borgheresi A, Balestrieri F, Zaccara G, Inghilleri M, Berardelli A. Modulatory effects of high-frequency repetitive transcranial magnetic stimulation on the ipsilateral silent period. *Exp Brain Res*. 2006 Jun;171(4):490-6
- 63: Cincotta M, Borgheresi A, Jung P, Balestrieri F, Giovannelli F, Zaccara G, Ziemann U. Physical interactions between induced electrical fields can have substantial effects on neuronal excitation during simultaneous TMS of two brain areas. *Clin Neurophysiol*. 2005 Jul;116(7):1733-42.
- 64: Piccininni M, Di Carlo A, Baldereschi M, Zaccara G, Inzitari D. Behavioral and psychological symptoms in Alzheimer's disease: frequency and relationship with duration and severity of the disease. *Dement Geriatr Cogn Disord*. 2005;19(5-6):276-81.
- 65: Zaccara G, Cincotta M, Borgheresi A, Balestrieri F. Adverse motor effects induced by antiepileptic drugs. *Epileptic Disord*. 2004 Sep;6(3):153-68.

- 66: Cincotta M, Borgheresi A, Balestrieri F, Giovannelli F, Rossi S, Ragazzoni A, Zaccara G, Ziemann U. Involvement of the human dorsal premotor cortex in unimanual motor control: an interference approach using transcranial magnetic stimulation. *Neurosci Lett*. 2004 Sep 2;367(2):189-93.
- 67: Cincotta M, Borgheresi A, Ragazzoni A, Vanni P, Balestrieri F, Benvenuti F, Zaccara G, Ziemann U. Motor control in mirror movements: studies with transcranial magnetic stimulation. *Suppl Clin Neurophysiol*. 2003;56:175-80.
- 68: Cincotta M, Borgheresi A, Balzini L, Vannucchi L, Zeloni G, Ragazzoni A, Benvenuti F, Zaccara G, Arnetoli G, Ziemann U. Separate ipsilateral and contralateral corticospinal projections in congenital mirror movements: Neurophysiological evidence and significance for motor rehabilitation. *Mov Disord*. 2003 Nov;18(11):1294-300.
- 69: Cincotta M, Borgheresi A, Gambetti C, Balestrieri F, Rossi L, Zaccara G, Ulivelli M, Rossi S, Civardi C, Cantello R. Suprathreshold 0.3 Hz repetitive TMS prolongs the cortical silent period: potential implications for therapeutic trials in epilepsy. *Clin Neurophysiol*. 2003 Oct;114(10):1827-33.
- 70: Tassinari CA, Cincotta M, Zaccara G, Michelucci R. Transcranial magnetic stimulation and epilepsy. *Clin Neurophysiol*. 2003 May;114(5):777-98.
- 71: Cincotta M, Borgheresi A, Balestrieri F, Zaccara G. Reduced inhibition within primary motor cortex in patients with poststroke focal motor seizures. *Neurology*. 2003 Feb 11;60(3):527-8; author reply 527-8.
- 72: Ragazzoni A, Cincotta M, Borgheresi A, Zaccara G, Ziemann U. Congenital hemiparesis: different functional reorganization of somatosensory and motor pathways. *Clin Neurophysiol*. 2002 Aug;113(8):1273-8.
- 73: Cincotta M, Borgheresi A, Boffi P, Vigliano P, Ragazzoni A, Zaccara G, Ziemann U. Bilateral motor cortex output with intended unimanual contraction in congenital mirror movements. *Neurology*. 2002 Apr 23;58(8):1290-3.
- 74: Cincotta M, Borgheresi A, Benvenuti F, Liotta P, Marin E, Zaccara G. Cortical silent period in two patients with meningioma and preoperative seizures: a pre-and postsurgical follow-up study. *Clin Neurophysiol*. 2002 Apr;113(4):597-603.
- 75: Zaccara G, Cornaggia CM. The use of antidepressant and antipsychotic drugs in elderly epilepsy patients. *Epilepsia*. 2002;43 Suppl 2:32-6. Review. PubMed PMID: 11903481.
- 76: Cincotta M, Tozzi F, Zaccara G, Borgheresi A, Lori S, Cosottini M, Cantello R. Motor imagery in a locked-in patient: evidence from transcranial magnetic stimulation. *Ital J Neurol Sci*. 1999 Feb;20(1):37-41.
- 77: Cincotta M, Borgheresi A, Guidi L, Macucci M, Cosottini M, Lambruschini P, Benvenuti F, Zaccara G. Remote effects of cortical dysgenesis on the primary motor cortex: evidence from the silent period following transcranial magnetic stimulation. *Clin Neurophysiol*. 2000 Aug;111(8):1340-5.
- 78: Cincotta M, Borgheresi A, Liotta P, Montigiani A, Marin E, Zaccara G, Ziemann U. Reorganization of the motor cortex in a patient with congenital hemiparesis and mirror movements. *Neurology*. 2000 Jul 12;55(1):129-31.
- 79: Ragazzoni A, Grippo A, Tozzi F, Zaccara G. Event-related potentials in patients with total locked-in state due to fulminant Guillain-Barré syndrome. *Int J Psychophysiol*. 2000 Jul;37(1):99-109.
- 80: Di Russo F, Zaccara G, Ragazzoni A, Pallanti S. Abnormal visual event-related potentials in obsessive-compulsive disorder without panic disorder or depression comorbidity. *J Psychiatr Res*. 2000 Jan-Feb;34(1):75-82.
- 81: Messori A, Trippoli S, Becagli P, Zaccara G. Cost effectiveness of riluzole in amyotrophic lateral sclerosis. Italian Cooperative Group for the Study of Meta-Analysis and the Osservatorio SIFO sui Farmaci. *Pharmacoeconomics*. 1999 Aug;16(2):153-63.
- 82: Cincotta M, Borgheresi A, Lori S, Fabbri M, Zaccara G. Interictal inhibitory mechanisms in patients with cryptogenic motor cortex epilepsy: a study of the silent period following transcranial magnetic stimulation. *Electroencephalogr Clin Neurophysiol*. 1998 Jul;107(1):1-7.
- 83: Pallanti S, Quercioli L, Zaccara G, Ramacciotti AB, Arnetoli G. Eye movement abnormalities in anorexia nervosa. *Psychiatry Res*. 1998 Mar 20;78(1-2):59-70.
- 84: Messori A, Trippoli S, Becagli P, Cincotta M, Labbate MG, Zaccara G. Adjunctive lamotrigine therapy in patients with refractory seizures: a lifetime cost-utility analysis. *Eur J Clin Pharmacol*. 1998 Feb;53(6):421-7.
- 85: Cosottini M, Mascalchi M, Zaccara G, Arnetoli G. Reversal of syphilitic hydrocephalus with intravenous penicillin. *Can J Neurol Sci*. 1997 Nov;24(4):343-4.
- 86: Lådavas E, Zeloni G, Zaccara G, Gangemi P. Eye movements and orienting of attention in patients with visual neglect. *J Cogn Neurosci*. 1997 Jan;9(1):67-74. doi: 10.1162/jocn.1997.9.1.67.
- 87: Toscani L, Gangemi PF, Parigi A, Silipo R, Ragghianti P, Sirabella E, Morelli M, Bagnoli L, Vergassola R, Zaccara G. Human heart rate variability and sleep stages. *Ital J Neurol Sci*. 1996 Dec;17(6):437-9.

- 88: Pallanti S, Grecu LM, Gangemi PF, Massi S, Parigi A, Arnetoli G, Quercioli L, Zaccara G. Smooth-pursuit eye movement and saccadic intrusions in obsessive-compulsive disorder. *Biol Psychiatry*. 1996 Dec 1;40(11):1164-72.
- 89: Gatti G, Bartoli A, Marchiselli R, Michelucci R, Tassinari CA, Pisani F, Zaccara G, Timmings P, Richens A, Perucca E. Vigabatrin-induced decrease in serum phenytoin concentration does not involve a change in phenytoin bioavailability. *Br J Clin Pharmacol*. 1993 Dec;36(6):603-6.
- 90: Zaccara G, Gangemi PF, Bendoni L, Menge GP, Schwabe S, Monza GC. Influence of single and repeated doses of oxcarbazepine on the pharmacokinetic profile of felodipine. *Ther Drug Monit*. 1993 Feb;15(1):39-42.
- 91: Zaccara G, Gangemi PF, Muscas GC, Paganini M, Pallanti S, Parigi A, Messori A, Arnetoli G. Smooth-pursuit eye movements: alterations in Alzheimer's disease. *J Neurol Sci*. 1992 Oct;112(1-2):81-9.
- 92: Zaccara G, Gangemi PF, Messori A, Parigi A, Massi S, Valenza T, Monza GC. Effects of oxcarbazepine and carbamazepine on the central nervous system: computerised analysis of saccadic and smooth-pursuit eye movements. *Acta Neurol Scand*. 1992 Jun;85(6):425-9.
- 93: Benvenuti F, Bandinelli S, Mencarelli MA, Lunardelli ML, Campostrini R, Zaccara G, Pantaleo T. Alterations of ballistic movements in epileptic patients with phenytoin intoxication. *Epilepsia*. 1992 Mar-Apr;33(2):376-88.
- 94: Zaccara G, Baldini S, Gangemi PF, Messori A, Parigi A, Nencioni C. A new method for analyzing smooth-pursuit eye movements. Description of a microcomputer program and evaluation in healthy volunteers. *Ital J Neurol Sci*. 1991 Dec;12(6):537-44.
- 95: Gangemi PF, Messori A, Baldini S, Parigi A, Massi S, Zaccara G. Comparison of two nonlinear models for fitting saccadic eye movement data. *Comput Methods Programs Biomed*. 1991 Apr;34(4):291-7.
- 96: Riva R, Zaccara G, Albani F, Galli G, Campostrini R, Paganini M, Baruzzi A. Effects of acute valproic acid administration on carnitine plasma concentrations in epileptic patients. *Epilepsy Res*. 1991 Mar;8(2):149-52.
- 97: Gangemi PF, Cellerini M, Massi S, Mascacchi M, De Cristofaro MT, Pupi A, Zaccara G, Muscas GC. [MRI and HM-PAO SPECT in 20 patients with drug-resistant partial epilepsy]. *Riv Neurol*. 1990 Nov-Dec;60(6):247-9. Italian
- 98: Gangemi PF, Massi S, Paganini M, Parigi A, Cellerini M, Arnetoli G, Zaccara G. [Alterations of smooth-pursuit ocular movements in Alzheimer's disease]. *Riv Neurol*. 1990 Sep-Oct;60(5):211-4. Italian.
- 99: Canger R, Altamura AC, Belvedere O, Monaco F, Monza GC, Muscas GC, Mutani R, Panetta B, Pisani F, Zaccara G, et al. Conventional vs controlled-release carbamazepine: a multicentre, double-blind, cross-over study. *Acta Neurol Scand*. 1990 Jul;82(1):9-13.
- 100: Zaccara G, Muscas GC, Messori A. Clinical features, pathogenesis and management of drug-induced seizures. *Drug Saf*. 1990 Mar-Apr;5(2):109-51
- 101: Zaccara G, Messori A, Muscas GC, Albani F, Baruzzi A, Bianchi A, Riva R, Valenza T, Zagnoni P, Zolo P, et al. Predictive performance of pharmacokinetic methods for phenytoin dosing: a multi-center evaluation in 282 patients with epilepsy. *Epilepsy Res*. 1989 May-Jun;3(3):253-61.
- 102: Zaccara G, Messori A, Moroni F. Clinical pharmacokinetics of valproic acid--1988. *Clin Pharmacokinet*. 1988 Dec;15(6):367-89. Review.
- 103: Dolara P, Lodovici M, Salvadori M, Zaccara G, Muscas GC. Urinary 6-beta-OH-cortisol and paracetamol metabolites as a probe for assessing oxidation and conjugation of chemicals in humans. *Pharmacol Res Commun*. 1987 Apr;19(4):261-73.
- 104: Paganini M, Zaccara G, Moroni F, Campostrini R, Bendoni L, Arnetoli G, Zappoli R. Lack of relationship between sodium valproate-induced adverse effects and the plasma concentration of its metabolite 2-propylpenten-4-oic acid. *Eur J Clin Pharmacol*. 1987;32(2):219-22.
- 105: Zaccara G, Campostrini R, Paganini M, Messori A, Valenza T, Arnetoli G, Zappoli R. Long-term treatment with sodium valproate: monitoring of venous ammonia concentrations and adverse effects. *Ther Drug Monit*. 1987;9(1):34-40.
- 106: Mura P, Bramanti G, Liguori A, Polidori G, Santoni G, Landini A, Zaccara G, Muscas GC, Messori A. Bioavailability and clinical usefulness of low-strength tablets of phenytoin. *Farmaco Prat*. 1986 Oct;41(10):313-25.
- 107: Zaccara G, Innocenti P, Bartelli M, Casini R, Tozzi F, Rossi L, Zappoli R. Status epilepticus due to abrupt diazepam withdrawal: a case report. *J Neurol Neurosurg Psychiatry*. 1986 Aug;49(8):959-60.
- 108: Campostrini R, Zaccara G, Rossi L, Paganini M, Dorigotti A, Zappoli R. Valproate-induced hyperammonaemia in two epileptic identical twins. *J Neurol*. 1985;232(3):167-8.
- 109: Zaccara G, Paganini M, Campostrini R, Moroni F, Valenza T, Messori A, Bartelli M, Arnetoli G, Zappoli R. Effect of associated antiepileptic treatment on valproate-induced hyperammonemia. *Ther Drug Monit*. 1985;7(2):185-90.
- 110: Paganini M, Zaccara G, Campostrini R, Valenza T, Angelastro R, Bartelli M, Arnetoli G, Zappoli R. Venous blood ammonia concentrations in adult epileptic patients are increased by treatment with valproic acid. *Acta Neurol (Napoli)*. 1984 Dec;6(6):442-6.

111: Zaccara G, Campostrini R, Paganini M, Moroni F, Valenza T, Targioni G, Arnetoli G, Zappoli R, Baruzzi A. Acute changes of blood ammonia may predict short-term adverse effects of valproic acid. *Neurology*. 1984 Nov;34(11):1519-21.

112: Ruffo S, Matucci M, Longo G, Morfini M, Vannini S, Messori A, Donati-Cori G, Tendi E, Valenza T, Zaccara G, et al. A weighted least-squares approach for fitting to kinetic models the plasma concentration data of phenytoin and Factor VIII. *Farmaco Prat*. 1984 Jul;39(7):211-21.

113: Valenza T, Messori A, Zaccara G, Arnetoli G, Bartoli C, Donati-Cori G, Muscas GC, Silvano R, Tendi E, Zappoli R. Clinical application of the Mullen and Foster method for individualizing phenytoin dosage. *Ital J Neurol Sci*. 1984 Jun;5(2):195-200.

114: Zaccara G, Paganini M, Campostrini R, Arnetoli G, Zappoli R, Moroni F. Hyperammonemia and valproate-induced alterations of the state of consciousness. A report of 8 cases. *Eur Neurol*. 1984;23(2):104-12.

115: Messori A, Zaccara G, Valenza T, Arnetoli G, Bartoli C, Donati-Cori G, Muscas GC, Tendi E. Comparative analysis of the pharmacokinetic techniques available for individualizing phenytoin dosage. *J Clin Hosp Pharm*. 1983 Dec;8(4):357-65.

116: Messori A, Valenza T, Zaccara G, Arnetoli G, Bartoli C, Donati-Cori G, Tendi E, Zappoli R. A new programmable calculator procedure for individualizing phenytoin dosage. *Drug Intell Clin Pharm*. 1983 Dec;17(12):890-3.

117: Zaccara G, Boncinelli L, Paganini M, Campostrini R, Arnetoli G, Zappoli R. Treatment of epileptic patients with valproic acid does not modify plasma and urine short-chain-fatty acids. *Acta Neurol Scand*. 1983 Oct;68(4):241-7.

118: Zaccara G, Messori A, Valenza T, Arnetoli G, Bartoli C, Donati-Cori G, Muscas GC, Tendi E, Zappoli R. Comparison of two pharmacokinetic methods for individualizing phenytoin dosage. *Boll Chim Farm*. 1983 Mar;122(3):15-6S.

119: Zappoli R, Zaccara G, Rossi L, Arnetoli G, Amantini A. Combined partial temporal and secondary generalized status epilepticus. Report of a case with fear bouts followed by prolonged confusion. *Eur Neurol*. 1983;22(3):192-204.

120: Campostrini R, Paganini M, Boncinelli L, Zaccara G, Arnetoli G, Zappoli R. [Alterations of the state of consciousness induced by valproic acid: 6 case reports]. *Riv Patol Nerv Ment*. 1983 Jan-Feb;104(1):23-34

121: Faravelli C, Tonini R, Zaccara G, Marchetti G. [Third-generation antidepressive agents. Experience with 100 cases of primary depression treated with viloxazine, nomifensine and mianserin]. *Minerva Psichiatr*. 1981 Apr-Jun;22(2):79-83.

122: Zagnoni P, Leone L, Baruzzi A, Benassi E, De Bernardi M, Frigo GM, Gerbino-Promis PC, Zaccara G. Antiepileptic drug therapy and plasma levels in 2500 patients from Northern Italy. *Monogr Neural Sci*. 1980;5:183-9.

123: Zaccara G, Ferrara M, Ardito P. [Controlled clinical trial of nomifensine in treatment of depression (author's transl)]. *Riv Patol Nerv Ment*. 1979 May-Jun;100(3):111-20

124: Zaccara G, Galli A. Effectiveness of simplified dosage schedules on the management of ambulant epileptic patients. *Eur Neurol*. 1979;18(5):341-4.

125: Zaccara G, Amantini A, Ciardella F, Franchi F, Rossi L, Zappoli Thyron E, Zappoli R. [Confusional states of epileptic nature with onset at menopause. Clinical studies of a case]. *Riv Neurobiol*. 1978 Oct-Dec;24(4):324-42.

126: Zaccara G, Galli A, Rossi L, Zappoli R, Zatelli L, Amaducci L. [Plasma levels of diphenylhydantoin (DPH) and phenobarbitone (PB) in epileptic patients resistant to drug treatment (author's transl)]. *Riv Patol Nerv Ment*. 1977

Nov-Dec;98(6):363-7